Angiex key facts
as of Oct 2026- Developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis.
- Angiex is valued at approximately $182.6M as of Oct 2026 (last reported valuation).
- It has raised $98.7M across 2 recorded rounds; the latest was Early Stage VC ($22.0M) in Jul 2025.
- Notable investors include MassChallenge, Mana Ventures, Gaingels, Keiretsu Forum, K5 Global — 19 tracked in total.
- Angiex has filed 3 Form Ds with the SEC since 2017, most recently Sep 2025 ($22.0M sold to 137 investors).
- Status: Privately Held (backing).
Angiex's last reported valuation, Aug 2021. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Angiex: the Monday email on marks, rounds and moves
Angiex funding rounds
2 roundsWho backs Angiex
19+Angiex valuation
Angiex's last reported valuation was $183 million in Aug 2021. No priced round, secondary trade or fund mark has surfaced since.
How much has Angiex raised?
Angiex has raised $98.7 million in total; 2 of its rounds are on record. The largest on record was a $2.9 million seed round in Jul 2017; the most recent was a $22 million early-stage round in Jul 2025.
Angiex has filed 3 Form Ds with the SEC since 2017, most recently in Sep 2025 ($22 million sold to 137 investors).
Angiex investors
19 investors are on record for Angiex, including MassChallenge, Mana Ventures, Gaingels and Keiretsu Forum. By type, the record holds 3 venture capital firms and 3 family offices. The early-stage round in Jul 2025 drew 137 investors.
About Angiex
Developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis. The company's antibody-drug conjugate therapy for solid cancers enables rapid development of nuclear-delivered antibody-drug conjugates that deliver conjugated payloads directly to the nucleus in tumor cells and to the activated endothelium of cancers and inflamed vessels, enabling healthcare providers to cure human cancers such as pancreatic, lung, and liver cancers and glioblastoma multiforme.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2015
- Employees
- 5
- Website
- angiex.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.